Analysts forecast that Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) will announce sales of $21.95 million for the current quarter, Zacks reports. Five analysts have provided estimates for Alnylam Pharmaceuticals’ earnings. The highest sales estimate is $27.70 million and the lowest is $15.44 million. Alnylam Pharmaceuticals reported sales of $21.90 million during the same quarter last year, which would suggest a positive year over year growth rate of 0.2%. The firm is expected to report its next earnings results on Thursday, May 2nd.
On average, analysts expect that Alnylam Pharmaceuticals will report full year sales of $139.42 million for the current fiscal year, with estimates ranging from $91.19 million to $203.96 million. For the next fiscal year, analysts anticipate that the firm will report sales of $363.32 million, with estimates ranging from $253.04 million to $435.23 million. Zacks’ sales averages are a mean average based on a survey of sell-side analysts that cover Alnylam Pharmaceuticals.
Get Alnylam Pharmaceuticals alerts:
Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, February 7th. The biopharmaceutical company reported ($2.09) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.27) by $0.18. Alnylam Pharmaceuticals had a negative return on equity of 50.82% and a negative net margin of 1,016.58%. The business had revenue of $21.00 million for the quarter, compared to the consensus estimate of $18.03 million. During the same quarter in the previous year, the company posted ($1.20) earnings per share. Alnylam Pharmaceuticals’s revenue for the quarter was down 44.6% compared to the same quarter last year.
A number of research analysts have recently weighed in on the company. Cowen reiterated a “buy” rating on shares of Alnylam Pharmaceuticals in a report on Wednesday, March 6th. Evercore ISI upgraded Alnylam Pharmaceuticals from an “in-line” rating to an “outperform” rating in a report on Wednesday, March 6th. Morgan Stanley upgraded Alnylam Pharmaceuticals from an “equal weight” rating to an “overweight” rating and set a $122.00 price target on the stock in a report on Tuesday, March 5th. BidaskClub upgraded Alnylam Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday, March 1st. Finally, Needham & Company LLC reiterated a “buy” rating and set a $135.00 price target on shares of Alnylam Pharmaceuticals in a report on Friday, February 8th. One analyst has rated the stock with a sell rating, four have given a hold rating and sixteen have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $133.28.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. FMR LLC boosted its position in Alnylam Pharmaceuticals by 0.4% during the fourth quarter. FMR LLC now owns 15,154,553 shares of the biopharmaceutical company’s stock valued at $1,104,919,000 after purchasing an additional 54,637 shares during the last quarter. Vanguard Group Inc. boosted its position in Alnylam Pharmaceuticals by 0.9% during the third quarter. Vanguard Group Inc. now owns 7,605,253 shares of the biopharmaceutical company’s stock valued at $665,612,000 after purchasing an additional 66,740 shares during the last quarter. Vanguard Group Inc boosted its position in Alnylam Pharmaceuticals by 0.9% during the third quarter. Vanguard Group Inc now owns 7,605,253 shares of the biopharmaceutical company’s stock valued at $665,612,000 after purchasing an additional 66,740 shares during the last quarter. BlackRock Inc. boosted its position in Alnylam Pharmaceuticals by 1.0% during the fourth quarter. BlackRock Inc. now owns 6,145,805 shares of the biopharmaceutical company’s stock valued at $448,089,000 after purchasing an additional 61,777 shares during the last quarter. Finally, Baillie Gifford & Co. boosted its position in Alnylam Pharmaceuticals by 6.4% during the fourth quarter. Baillie Gifford & Co. now owns 4,746,850 shares of the biopharmaceutical company’s stock valued at $346,093,000 after purchasing an additional 284,024 shares during the last quarter. 88.62% of the stock is owned by hedge funds and other institutional investors.
Shares of ALNY stock traded up $3.79 on Friday, reaching $91.76. 625,642 shares of the company’s stock traded hands, compared to its average volume of 850,265. Alnylam Pharmaceuticals has a 12-month low of $60.27 and a 12-month high of $153.99. The company has a current ratio of 6.69, a quick ratio of 6.56 and a debt-to-equity ratio of 0.02. The company has a market capitalization of $9.35 billion, a price-to-earnings ratio of -12.12 and a beta of 2.54.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference (RNAi). Its pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases. The company's clinical development programs include Patisiran, which is in Phase III clinical trial for the treatment of hereditary transthyretin-mediated amyloidosis; Givosiran that is in Phase III trial to treat acute hepatic porphyrias; Fitusiran, an investigational RNAi therapeutic that is in Phase II open-label extension and Phase III clinical trial for the treatment of hemophilia and rare bleeding disorders; and Inclisiran, which is in III clinical trial for hypercholesterolemia.
Featured Story: Gross Domestic Product (GDP)
Get a free copy of the Zacks research report on Alnylam Pharmaceuticals (ALNY)
For more information about research offerings from Zacks Investment Research, visit Zacks.com